The agreement with Lemonaid Health, a leading telemedicine provider, is likely to enhance the accessibility and distribution of STENDRA, potentially leading to increased sales and a stronger market presence for Petros Pharmaceuticals. The partnership taps into the growing telemedicine market, which could significantly benefit PTPI by reaching a wider audience of ED patients seeking convenient treatment options.